Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%

NCT00138593 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: vildagliptin

Sponsor

Novartis